EaStCHEM School of Chemistry, University of Edinburgh, Joseph Black Building, David Brewster Rd, Edinburgh, EH9 3FJ, UK.
Curr Opin Chem Biol. 2020 Oct;58:63-71. doi: 10.1016/j.cbpa.2020.06.004. Epub 2020 Aug 5.
Combining organometallics and biology has generated broad interest from scientists working on applications from in situ drug release to biocatalysis. Engineered enzymes and biohybrid catalysts (also referred to as artificial enzymes) have introduced a wide range of abiotic chemistry into biocatalysis. Predominantly, this work has concentrated on using these catalysts for single step in vitro reactions. However, the promise of using these hybrid catalysts in vivo and combining them with synthetic biology and metabolic engineering is vast. This report will briefly review recent advances in artificial metalloenzyme design, followed by summarising recent studies that have looked at the use of these hybrid catalysts in vivo and in enzymatic cascades, therefore exploring their potential for synthetic biology.
将金属有机化学和生物学结合在一起,引起了从事从原位药物释放到生物催化等应用研究的科学家们的广泛兴趣。经过设计的酶和生物杂化催化剂(也称为人工酶)已经将广泛的非生物化学物质引入到生物催化中。主要是,这项工作集中在使用这些催化剂进行单一的体外反应。然而,在体内使用这些杂化催化剂并将其与合成生物学和代谢工程相结合的前景是广阔的。本报告将简要回顾人工金属酶设计的最新进展,然后总结最近研究这些杂化催化剂在体内和酶级联反应中的应用,从而探索它们在合成生物学中的潜力。